SARS-CoV-2 pseudovirus enters the host cells through spike protein-CD147 in an Arf6-dependent mannerSARS-CoV-2 슈도바이러스는 Arf6 의존적 방식으로 스파이크 단백질-CD147을 통해 숙주 세포에 들어갑니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approach Arf6 blockade CD147 cells clathrin Clathrin-mediated endocytosis clinically coronavirus endocytic endocytic mechanism endocytosis evaluate feasible function host cell host cells Huh-7 cell Huh-7 cells independent independent of indicated infected Vero E6 cells Infection inhibited inhibitor knockdown Localization macropinocytosis pathway Prevent pseudovirus pseudovirus infection public health RAB5A SARS-CoV-2 SARS-CoV-2 entry SARS-COV-2 infection SARS-CoV-2 pseudovirus SARS-CoV-2 pseudovirus infection severe acute respiratory syndrome Coronavirus Spike protein spike protein. Spread the SARS-CoV-2 variant Vero E6 VERO E6 cells viral infection weakened [DOI] 10.1080/22221751.2022.2059403 PMC 바로가기 [Article Type] Article
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses중증 급성 호흡기 증후군 코로나바이러스 2 백신 접종은 계절성 인간 코로나바이러스에 대한 중화 활성을 향상시킵니다Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 치료법, [키워드] 229E activity acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Against analyzed average BNT162b2 causative agent ChAdOx1 ChAdOx1 nCoV-19 circulating colds common cold Concentration coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccinations cross-neutralization cross-protection determined by Efficiency Endemic Gene Expression HCoV HCoV-229E HCoV-NL63 HCoV-OC43 HCoVs Heterologous Huh-7 cells Human human coronavirus incubated individual inhibitory activity MERS MERS-CoV Middle East Middle East respiratory syndrome MOST neutralization neutralize Neutralizing activity NL63 nucleocapsid expression OC43 Preexisting immunity pseudoparticle pseudovirion pseudovirions reporter reporter gene respiratory SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 vaccination seasonal seasonal coronavirus seasonal coronaviruses seasonal coronaviruses. sera severe acute respiratory syndrome Coronavirus significantly increased Spike proteins these viruses vaccination Viral RNA virus [DOI] 10.1093/cid/ciac057 PMC 바로가기 [Article Type] Article
Palmitoylethanolamide (PEA) Inhibits SARS-CoV-2 Entry by Interacting with S Protein and ACE-2 Receptor팔미토일에탄올아미드(PEA)는 S 단백질 및 ACE-2 수용체와 상호작용하여 SARS-CoV-2 진입을 억제합니다Article Published on 2022-05-172022-09-11 Journal: Viruses [Category] COVID19(2023년), SARS, 치료제, [키워드] ACE-2 activate activated adjuvant therapy Antiviral antiviral agent antiviral drug antiviral drugs antiviral potency binding bioactive lipids cascade cause cellular clinical test Clinical tests clinical trial connection Coronaviruses counteract Course COVID-19 COVID-19 pandemic Degradation derangement Disruption drop droplets energy entry receptor event Evidence fatty Fatty acid generate glycoprotein Glycoproteins highlight Huh-7 cells humans in viral Infection Inflammation inflammatory stimuli lack life cycle Lipid lipid droplets lipid metabolism lipids mechanism of action mechanisms membrane metabolism nutraceutical palmitoylethanolamide Pathways PEA Prevent protective effect Protective effects recent replicate Replication Research RNA virus S protein SARS-CoV-2 SARS-CoV-2 entry SARS-CoV-2 S protein second significantly Spike protein spike protein. the SARS-CoV-2 therapy Toxicity transcription factor Treatment Usage viral infection viral life cycle virus viruses VSV [DOI] 10.3390/v14051080 PMC 바로가기 [Article Type] Article
Inhibition of Autophagy Suppresses SARS-CoV-2 Replication and Ameliorates Pneumonia in hACE2 Transgenic Mice and Xenografted Human Lung Tissues자가포식 억제는 SARS-CoV-2 복제를 억제하고 hACE2 형질전환 마우스 및 이종이식 인간 폐 조직에서 폐렴을 개선합니다Article Published on 2021-11-232022-09-11 Journal: Journal of Virology [Category] SARS, 유전자 메커니즘, [키워드] 3-MA accompanied Activation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 angiotensin animal model animal models anti-SARS-CoV-2 therapeutics Atg13 ATG14 Atg5 autophagic autophagy autophagy-inhibiting agent autophagy-inhibiting agents autophagy. block caused Combination complex Complexes contribute coronavirus Crab-eating macaque Critical elements enzyme events experimental evidence global pandemic hACE2 Huh-7 cells Human human Angiotensin-converting enzyme Human angiotensin-converting enzyme 2 human lung human lung tissue IMPROVE in vitro in vivo induce Infection inhibit inhibition insight interfere involved mechanism mice modulation mouse mTOR pathway Pneumonia potential therapeutic target potential therapeutic targets SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 suppresse therapeutic agent therapeutic agents thought tissues transgenic mice Transgenic mouse Vero E6 virus infection Virus-host interaction Virus-host interactions Vps34 [DOI] 10.1128/JVI.01537-21 PMC 바로가기 [Article Type] Article
AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19Antiviral Agents Published on 2021-02-082022-10-27 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID-19, [키워드] acute respiratory syndrome Administered Antiviral approved AT-511 AT-527 AT-9010 cells Concentration coronavirus Coronavirus-2 Coronaviruses COVID-19 cytotoxicity distribution dose effective FDA Guanosine HCoV-OC43 hepatitis C virus Huh-7 cells human airway epithelial human lung in vitro activity incubated inhibit lung metabolite nasal epithelial cell nucleotide oral pharmacokinetic pharmacokinetic data potent predict prodrug Remdesivir replication of SARS-CoV-2 required Result SARS-CoV SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication shown subject subjects tissue treat Treatment triphosphate [DOI] 10.1128/AAC.02479-20 PMC 바로가기 [Article Type] Antiviral Agents
AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19Antiviral Agents Published on 2021-02-082022-10-27 Journal: Antimicrobial Agents and Chemotherapy [Category] Coronavirus, COVID-19, SARS, [키워드] acute respiratory syndrome Administered Antiviral approved AT-511 AT-527 AT-9010 cells Concentration coronavirus Coronavirus-2 Coronaviruses COVID-19 cytotoxicity distribution dose effective FDA Guanosine HCoV-OC43 hepatitis C virus Huh-7 cells human airway epithelial human lung in vitro activity incubated inhibit lung metabolite nasal epithelial cell nucleotide oral pharmacokinetic pharmacokinetic data potent predict prodrug Remdesivir replication of SARS-CoV-2 required Result SARS-CoV SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication shown subject subjects tissue treat Treatment triphosphate [DOI] 10.1128/AAC.02479-20 PMC 바로가기 [Article Type] Antiviral Agents
AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19구아노신 뉴클레오티드 유사체의 이중 전구약물인 AT-527은 시험관 내 SARS-CoV-2의 강력한 억제제이자 COVID-19 치료를 위한 유망한 경구 항바이러스제입니다Antiviral Agents Published on 2021-02-082022-08-31 Journal: Antimicrobial Agents and Chemotherapy [Category] 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Administered Antiviral approved AT-511 AT-527 AT-9010 causative agent cells Concentration coronavirus Coronavirus-2 Coronaviruses COVID-19 cytotoxicity distribution dose effective epithelial cells FDA Guanosine half-life HCoV HCoV-OC43 hepatitis C hepatitis C virus Huh-7 cells human airway epithelial Human coronavirus human lung in vitro activity incubated inhibit lung metabolite nasal epithelial cell nucleotide OC43 oral pharmacokinetic pharmacokinetic data potent predict prodrug Remdesivir Replication replication of SARS-CoV-2 required respiratory Result SARS-CoV SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus shown subject subjects tissue treat Treatment triphosphate [DOI] 10.1128/AAC.02479-20 PMC 바로가기 [Article Type] Antiviral Agents
A Single V672F Substitution in the Spike Protein of Field-Isolated PEDV Promotes Cell–Cell Fusion and Replication in VeroE6 CellsArticle Published on 2019-03-202022-10-28 Journal: Viruses [Category] Coronavirus, [키워드] Amino acid amino acid residue aminopeptidase N analysis cell lines cell–cell fusion cells characterized chimeric chimeric proteins Critical demonstrated Efficiency Enterocyte epidemic diarrhea expressing fusion host cells Huh-7 cells identify induce infect Mutation Neonatal passages PEDV RBD receptor Receptor binding domain receptor preference replaced replicate responsible S protein S proteins S1/S2 cleavage site single mutation spike Substitution Syncytia syncytium syncytium formation the RBD the Spike the spike protein triggered variant VeroE6 cell virus virus while [DOI] 10.3390/v11030282 PMC 바로가기 [Article Type] Article
Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In VitroArticle Published on 2018-05-242022-10-28 Journal: Viruses [Category] Coronavirus, [키워드] acute respiratory illness acute respiratory syndrome anticancer antiviral activity approved drug Arabian Peninsula cause clinically Combination composed compounds country current drug drug candidates early stage exhibited Fatality rate gemcitabine Huh-7 cells Human human infection in vitro infected individual inhibit inhibitor kinase MERS-CoV MERS-CoV infection Middle East Middle East respiratory syndrome occurred outbreak pathogen Replication respiratory RNA viruses saracatinib Saudi Arabia screened signaling pathways South Korea spread to Src-family kinase inhibitor synergistic therapeutic option Treatment tyrosine viral life cycle zoonotic [DOI] 10.3390/v10060283 PMC 바로가기 [Article Type] Article